Structural imaging in the presymptomatic stage of genetically determined parkinsonism

Neurobiology of Disease

Volumn 39, Issue 3, 2010, Pages 402-408

  Reetz, Kathrin ^a   Tadic, Vera ^b   Kasten, Meike ^b   Brüggemann, Norbert ^b   Schmidt, Alexander ^b   Hagenah, Johann ^b   Pramstaller, Peter P ^c   Ramirez, Alfredo ^c   Behrens, Maria I ^d   Siebner, Hartwig R ^e   Klein, Christine ^b   Binkofski, Ferdinand ^f  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c INSTITUTE FOR RENEWABLE ENERGY   (Italy)

^d HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^e HVIDOVRE HOSPITAL   (Denmark)

^f RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

ATP13A2; Compensation; Genetic parkinsonism; LRRK2; Magnetic resonance imaging (MRI); Parkin; PINK1; Presymptomatic stage; Striatum; Voxel based morphometry (VBM)

Indexed keywords

GENE PRODUCT; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE INDUCED PUTATIVE KINASE 1; PROTEIN ATP13A2; PROTEIN PINK1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; GENE MUTATION; GRAY MATTER; HETEROZYGOTE; HUMAN; IMAGE ANALYSIS; MENTAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL LOBE; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TEMPORAL CORTEX; VOXEL BASED MORPHOMETRY;

EID: 77954953565     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.05.006     Document Type: Article

References (74)

1. Abou-Sleiman P.M., Muqit M.M., McDonald N.Q., Yang Y.X., Gandhi S., Healy D.G., Harvey K., Harvey R.J., Deas E., Bhatia K., Quinn N., Lees A., Latchman D.S., Wood N.W. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann. Neurol. 2006, 60:414-419.
2. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-2785.
3. Anderson B.J., Eckburg P.B., Relucio K.I. Alterations in the thickness of motor cortical subregions after motor-skill learning and exercise. Learn. Mem. 2002, 9:1-9.
4. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
5. Benedetti F., Bernasconi A., Pontiggia A. Depression and neurological disorders. Curr. Opin. Psychiatry 2006, 19:14-18.
6. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
7. Binkofski F., Reetz K., Gaser C., Hilker R., Hagenah J., Hedrich K., van Eimeren T., Thiel A., Buchel C., Pramstaller P.P., Siebner H.R., Klein C. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 2007, 69:842-850.
8. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am. J. Psychiatry 2000, 157:115-118.
9. Brüggemann, N., Hagenah, J., Reetz, K., Schmidt, A., Kasten, M., Buchmann, I., Eckerle, S., Bähre, M., Münchau, A., Djarmati, A., Von der Vegt, J., Siebner, H.R., Binkofski, F., Ramirez, A., Behrens, M., Klein, C., 2010. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Archives of Neurology, in press.
10. Buhmann C., Binkofski F., Klein C., Buchel C., van Eimeren T., Erdmann C., Hedrich K., Kasten M., Hagenah J., Deuschl G., Pramstaller P.P., Siebner H.R. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 2005, 128:2281-2290.
11. Camicioli R., Moore M.M., Kinney A., Corbridge E., Glassberg K., Kaye J.A. Parkinson's disease is associated with hippocampal atrophy. Mov. Disord. 2003, 18(7):784-790.
12. Cavanna A.E., Trimble M.R. The precuneus: a review of its functional anatomy and behavioural correlates. Brain 2006, 129:564-583.
13. Chen-Plotkin A.S., Yuan W., Anderson C., McCarty Wood E., Hurtig H.I., Clark C.M., Miller B.L., Lee V.M., Trojanowski J.Q., Grossman M., Van Deerlin V.M. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 2008, 70:521-527.
14. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
15. Deuschl G., Wilms H. Clinical spectrum and physiology of palatal tremor. Mov. Disord. 2002, 17(Suppl 2):S63-66.
16. Dhikav V., Anhand K.S. Is hyppocampal atrophy a future drug target?. Medical Hypotheses 2007, 68:1300-1306.
17. Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F., Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S., Breedveld G., Sampaio C., Meco G., Barbosa E., Oostra B.A., Bonifati V. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005, 365:412-415.
18. Draganski B., Gaser C., Busch V., Schuierer G., Bogdahn U., May A. Neuroplasticity: changes in grey matter induced by training. Nature 2004, 427:311-312.
19. Draganski B., Gaser C., Kempermann G., Kuhn H.G., Winkler J., Buchel C., May A. Temporal and spatial dynamics of brain structure changes during extensive learning. J. Neurosci. 2006, 26:6314-6317.
20. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
21. Frodl T., Schaub A., Banac S., Charypar M., Jager M., Kummler P., Bottlender R., Zetzsche T., Born C., Leinsinger G., Reiser M., Moller H.J., Meisenzahl E.M. Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J. Psychiatry Neurosci. 2006, 31:316-325.
22. Gaig C., Ezquerra M., Marti M.J., Munoz E., Valldeoriola F., Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch. Neurol. 2006, 63:377-382.
23. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 2006, 59:315-322.
24. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J., Healy D.G., Holton J.L., Revesz T., Wood N.W. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
25. Gispert S., Ricciardi F., Kurz A., Azizov M., Hoepken H.H., Becker D., Voos W., Leuner K., Muller W.E., Kudin A.P., Kunz W.S., Zimmermann A., Roeper J., Wenzel D., Jendrach M., Garcia-Arencibia M., Fernandez-Ruiz J., Huber L., Rohrer H., Barrera M., Reichert A.S., Rub U., Chen A., Nussbaum R.L., Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS ONE 2009, 4:e5777.
26. Gitler A.D., Chesi A., Geddie M.L., Strathearn K.E., Hamamichi S., Hill K.J., Caldwell K.A., Caldwell G.A., Cooper A.A., Rochet J.C., Lindquist S. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 2009, 41:308-315.
27. Goldstein J.M., Goodman J.M., Seidman L.J., Kennedy D.N., Makris N., Lee H., Tourville J., Caviness V.S., Faraone S.V., Tsuang M.T. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. Arch. Gen. Psychiatry 1999, 56:537-547.
28. Goldwurm S., Zini M., Mariani L., Tesei S., Miceli R., Sironi F., Clementi M., Bonifati V., Pezzoli G. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007, 68:1141-1143.
29. Gur R.E., Turetsky B.I., Bilker W.B., Gur R.C. Reduced gray matter volume in schizophrenia. Arch. Gen. Psychiatry 1999, 56:905-911.
30. Haugarvoll K., Rademakers R., Kachergus J.M., Nuytemans K., Ross O.A., Gibson J.M., Tan E.K., Gaig C., Tolosa E., Goldwurm S., Guidi M., Riboldazzi G., Brown L., Walter U., Benecke R., Berg D., Gasser T., Theuns J., Pals P., Cras P., De Deyn P.P., Engelborghs S., Pickut B., Uitti R.J., Foroud T., Nichols W.C., Hagenah J., Klein C., Samii A., Zabetian C.P., Bonifati V., Van Broeckhoven C., Farrer M.J., Wszolek Z.K. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 2008, 70:1456-1460.
31. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira A.H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., Wood N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
32. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001, 11:520-528.
33. Heckers S., Konradi C. Hippocampal neurons in schizophrenia. J. Neural Transm. 2002, 109:891-905.
34. Heckers S., Heinsen H., Geiger B., Beckmann H. Hippocampal neuron number in schizophrenia. A stereological study. Arch. Gen. Psychiatry 1991, 48:1002-1008.
35. Hedrich K., Hagenah J., Djarmati A., Hiller A., Lohnau T., Lasek K., Grunewald A., Hilker R., Steinlechner S., Boston H., Kock N., Schneider-Gold C., Kress W., Siebner H., Binkofski F., Lencer R., Munchau A., Klein C. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit?. Arch. Neurol. 2006, 63:833-838.
36. Helsinki W.M.A.D. Ethical principles for medical research involving human subjects. Jama 2000, 284:3043-3045.
37. Hilker R., Klein C., Ghaemi M., Kis B., Strotmann T., Ozelius L.J., Lenz O., Vieregge P., Herholz K., Heiss W.D., Pramstaller P.P. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann. Neurol. 2001, 49:367-376.
38. Kantarci K., Jack C.R. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin. N. Am. 2003, 13:197-209.
39. Khan N.L., Brooks D.J., Pavese N., Sweeney M.G., Wood N.W., Lees A.J., Piccini P. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002, 125:2248-2256.
40. Khan N.L., Valente E.M., Bentivoglio A.R., Wood N.W., Albanese A., Brooks D.J., Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol. 2002, 52:849-853.
41. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., Wood N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
42. Khan N.L., Scherfler C., Graham E., Bhatia K.P., Quinn N., Lees A.J., Brooks D.J., Wood N.W., Piccini P. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 2005, 64:134-136.
43. Kleim J.A., Vij K., Ballard D.H., Greenough W.T. Learning-dependent synaptic modifications in the cerebellar cortex of the adult rat persist for at least four weeks. J. Neurosci. 1997, 17:717-721.
44. Klein C., Schlossmacher M.G. The genetics of Parkinson disease: Implications for neurological care. Nat. Clin. Pract. Neurol. 2006, 2:136-146.
45. Klein C., Schlossmacher M.G. The genetics of Parkinson disease: Implications for neurological care. Nature Clin. Neurol. 2006, 2(3):136-146.
46. Klein C., Pramstaller P.P., Kis B., Page C.C., Kann M., Leung J., Woodward H., Castellan C.C., Scherer M., Vieregge P., Breakefield X.O., Kramer P.L., Ozelius L.J. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann. Neurol. 2000, 48:65-71.
47. Laakso M.P., Partanen K., Riekkinen P., Lehtovirta M., Helkala E.L., Hallikainen M., Hanninen T., Vainio P., Soininen H. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Neurology 1996, 46:678-681.
48. Lohmann E., Periquet M., Bonifati V., Wood N.W., De Michele G., Bonnet A.M., Fraix V., Broussolle E., Horstink M.W., Vidailhet M., Verpillat P., Gasser T., Nicholl D., Teive H., Raskin S., Rascol O., Destee A., Ruberg M., Gasparini F., Meco G., Agid Y., Durr A., Brice A. How much phenotypic variation can be attributed to parkin genotype?. Ann. Neurol. 2003, 54:176-185.
49. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., Agid Y., Brice A. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J. Med. 2000, 342:1560-1567.
50. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003, 19:1233-1239.
51. McDonald C., Bullmore E.T., Sham P.C., Chitnis X., Wickham H., Bramon E., Murray R.M. Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch. Gen. Psychiatry 2004, 61(10):974-984.
52. Mervaala E., Fohr J., Kononen M., Valkonen-Korhonen M., Vainio P., Partanen K., Partanen J., Tiihonen J., Viinamaki H., Karjalainen A.K., Lehtonen J. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol. Med. 2000, 30:117-125.
53. Mori H., Kondo T., Yokochi M., Matsumine H., Nakagawa-Hattori Y., Miyake T., Suda K., Mizuno Y. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998, 51:890-892.
54. Najim al-Din A.S., Wriekat A., Mubaidin A., Dasouki M., Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 1994, 89:347-352.
55. Nichols T., Brett M., Andersson J., Wager T., Poline J.B. Valid conjunction inference with the minimum statistic. Neuroimage 2005, 25:653-660.
56. Paisan-Ruiz C., Saenz A., Lopez de Munain A., Marti I., Martinez Gil A., Marti-Masso J.F., Perez-Tur J. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann. Neurol. 2005, 57:365-372.
57. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
58. Pramstaller P.P., Schlossmacher M.G., Jacques T.S., Scaravilli F., Eskelson C., Pepivani I., Hedrich K., Adel S., Gonzales-McNeal M., Hilker R., Kramer P.L., Klein C. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann. Neurol. 2005, 58:411-422.
59. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., Al-Din A., Hillmer A.M., Karsak M., Liss B., Woods C.G., Behrens M.I., Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191.
60. Reetz K., Lencer R., Steinlechner S., Gaser C., Hagenah J., Büchel C., Petersen D., Kock N., Djarmati A., Siebner H.R., Klein C., Binkofski F. Limbic and frontal cortical degeneration is associated with psychiatric symptoms in PINK1 mutation carriers. Biol. Psych. 2008, 64:241-247.
61. Reetz K., Gaser C., Klein C., Hagenah J., Buchel C., Gottschalk S., Pramstaller P.P., Siebner H.R., Binkofski F. Structural findings in the basal ganglia in genetically determined and idiopathic Parkinson's disease. Mov. Disord. 2009, 24:99-103.
62. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., Litvan I., Gordon M.F., Wszolek Z.K., Farrer M.J., Dickson D.W. Lrrk2 and Lewy body disease. Ann. Neurol. 2006, 59:388-393.
63. Schlaepfer T.E., Harris G.J., Tien A.Y., Peng L.W., Lee S., Federman E.B., Chase G.A., Barta P.E., Pearlson G.D. Decreased regional cortical gray matter volume in schizophrenia. Am. J. Psychiatry 1994, 151:842-848.
64. Shah P.J., Ebmeier K.P., Glabus M.F., Goodwin G.M. Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br. J. Psychiatry 1998, 172:527-532.
65. Sheline Y.I., Sanghavi M., Mintun M.A., Gado M.H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 1999, 19:5034-5043.
66. Smith M.E. Bilateral hippocampal volume reduction in adults with post-traumatic stress disorder: a meta-analysis of structural MRI studies. Hippocampus 2005, 15:798-807.
67. Steinlechner S., Stahlberg J., Volkel B., Djarmati A., Hagenah J., Hiller A., Hedrich K., Konig I., Klein C., Lencer R. Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J. Neurol. Neurosurg. Psychiatry 2007, 78:532-535.
68. Trachtenberg J.T., Chen B.E., Knott G.W., Feng G., Sanes J.R., Welker E., Svoboda K. Longterm in vivo imaging of experience-dependent synaptic plasticity in adult cortex. Nature 2002, 420:788-794.
69. van de Warrenburg B.P., Lammens M., Lucking C.B., Denefle P., Wesseling P., Booij J., Praamstra P., Quinn N., Brice A., Horstink M.W. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001, 56:555-557.
70. van Nuenen B.F., Weiss M.M., Bloem B.R., Reetz K., van Eimeren T., Lohmann K., Hagenah J., Pramstaller P.P., Binkofski F., Klein C., Siebner H.R. Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 2009, 72:1041-1047.
71. Williams D.R., Hadeed A., al-Din A.S., Wreikat A.L., Lees A.J. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov. Disord. 2005, 20:1264-1271.
72. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157:16-25.
73. Wszolek Z.K., Pfeiffer R.F., Tsuboi Y., Uitti R.J., McComb R.D., Stoessl A.J., Strongosky A.J., Zimprich A., Muller-Myhsok B., Farrer M.J., Gasser T., Calne D.B., Dickson D.W. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004, 62:1619-1622.
74. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.